Company: CSTL
Filing Date: 2025-04-09
Form Type: DEF 14A
Source: 0001447362-25-000054
Chunk: 83

Company: CASTLE BIOSCIENCES INC
Filing Date: 2025-04-09
Form: DEF 14A
Chunk 83
---
ed Equity Awards 
 ($)*                                                                |     |           | Add: Year-End Fair Value of Equity Awards Granted During the Year 
 ($)*                                                              |     |           | Average Compensation Actually Paid 
 ($)                                |
| 2024 |     | 2,400,129 |                                                    |     | 1,502,419 |                                                            |     | — |                                                             |     | 281,748 |                                                             |     | 256,711 |                                                                     |     | 1,885,985 |                                                                   |     | 3,322,154 |                                    |

* There were no other assumptions made in the valuation of equity awards that differs materially from those disclosed as of the grant date of such equity awards.

(3) For each fiscal year disclosed the cumulative total shareholder return and peer group cumulative total shareholder return is calculated in the same manner as Item 201(e) of Regulation S-K assuming an initial investment of $100 on December 31, 2019. The peer group used in this calculation is the NASDAQ Biotechnology Total Return Index.

(4) The dollar amounts presented are from our consolidated financial statements appearing in our Annual Report on Form 10-K for each of the reported fiscal years.

(5) This is our Company-Selected Measure provided in accordance with Item 402(v)(2)(vi) of Regulation S-K. The dollar amounts presented are from our consolidated financial statements appearing in our Annual Report on Form 10-K for each of the reported fiscal years.

The following chart shows the relationships between (a) the compensation actually paid to the PEO, (b) the average compensation actually paid to the Non-PEO NEOs included in the Summary Compensation Table and (c) our company-selected measure of total revenue.

#### Castle Biosciences 2025 Proxy Statement77

#### Pay Versus Performance
The following chart shows the relationships between (a) the compensation actually paid to the PEO, (b) the average compensation actually paid to the Non-PEO NEOs included in the Summary Compensation Table and (c) our total shareholder return and the peer group total shareholder return.

The following chart shows the relationships between (a) the compensation actually paid to the PEO, (b) the average compensation actually paid to the Non-PEO NEOs in the Summary Compensation Table and (c) our net Income (loss).

#### 78Castle Biosciences 2025 Proxy Statement

#### Pay Versus Performance
The following performance measures are the Company’s most important performance measures used by